Only 20% of patients with metastatic gastric cancer in our study were tested for HER2 overexpression due to limited reimbursement for anti-HER2 therapy, which is restricted to the Civil Servant Medical Benefit Scheme. This evidence concerns the gene ERBB2 and gastric cancer.